Benign Prostatic Hyperplasia: Symptoms, Symptom Scores, and Outcome Measures

Thorner, Daniel; Weiss, Jeffrey P.

doi:10.1016/j.ucl.2009.07.001

Cited by 7 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In men with BOO/BPH, usually voiding symptoms are prevalent, and abnormal UF parameters are often associated with this condition (17). Conversely, our data showed that men with NP had no voiding symptoms, and both Q max and PVR were not associated with NP, because the UF outcomes did not significantly differ between men affected by NP and males without NP.…”

Section: Discussioncontrasting

confidence: 46%

Nocturnal polyuria in men performing uroflowmetry for lower urinary tract symptoms

Rubilotta

Castellani

Gubbiotti

et al. 2021

Arch Ital Urol Androl

View full text Add to dashboard Cite

Purpose: To assess the prevalence of nocturnal polyuria (NP) in males performing uroflowmetry (UF) for lower urinary tract symptoms (LUTS), the impact of NP on UF outcomes, and bladder emptying, the association between NP and LUTS. Materials and methods: Men scheduled for UF were recruited in two Centres. Data collected were medical history, IPSS, UF, post-void residual urine volume (PVR), 3-day frequency-volume charts (FVC). The NP index was used to assess NP with a threshold of ≥ 33%. The relationship between NP and patient’s aging was assessed. Results: 162 patients were included in the analysis. Mean age was 70.95 ± 8.04 years. The prevalence of NP was 54.9% (89/162). 110 (68%) patients reported nocturia, and among these, NP was documented in 76 (69%). Nocturia was found in 85% (76/89) of the population with NP. Total IPSS score, IPSS items #1, #2 and #7 showed a significant difference in men with NP compared with those without. Maximum flow rate and PVR did not significantly change comparing men with or without NP. Mean voiding volume (VV) of the night-time micturitions was significantly higher in men with NP compared to those without NP (532.1 ± 275.6 ml vs 175 ± 168.7 ml respectively, p < 0001), while mean VV day-time micturitions and mean VV at UF did not change between groups.Conclusions: NP had a high prevalence in men with LUTS performing UF. Aged males were more commonly affected by NP. Data demonstrated a strong relationship between NP and nocturia and increased urinary frequency while voiding symptoms were poorly related to NP.

show abstract

Section: Discussioncontrasting

confidence: 46%

Nocturnal polyuria in men performing uroflowmetry for lower urinary tract symptoms

Rubilotta

Castellani

Gubbiotti

et al. 2021

Arch Ital Urol Androl

View full text Add to dashboard Cite

show abstract

“…Benign prostatic hyperplasia (BPH) is a condition intimately related to ageing [8,9]. Although it is not life-threatening, its clinical manifestation as lower urinary tract symptoms (LUTS) reduces the patient's quality of life [10][11][12][13]. Troublesome LUTS can occur in up to 30% of men older than 65 years [14].…”

mentioning

confidence: 99%

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

Brisinda

Vanella²,

Marniga³

et al. 2011

CMC

View full text Add to dashboard Cite

Botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several disorders; the use of this agent has extended to a plethora of conditions including focal dystonia, spasticity, inappropriate contraction in most gastrointestinal sphincters, eye movement disorders, hyperhidrosis, genitourinary disorders and aesthetically undesirable hyperfunctional facial lines. In addition, BoNT is being investigated for the control of pain, and for the management of tension or migraine headaches and myofascial pain syndrome. Benign prostatic hyperplasia (BPH) is a common condition in ageing men; the goal of therapy is to reduce the lower urinary tract symptoms (LUTS) associated with BPH and to improve the quality of life. However, medical treatment, including drugs that relax smooth muscle within the prostate and drugs that shrink the gland are not totally effective or without complications. The standard surgical treatment for BPH is progressively changing to minimally invasive therapies, but none of them has provided clear results. The use of BoNT-A to inhibit the autonomic efferent effects on prostate growth and contraction, and inhibit the abnormal afferent effects on prostate sensation, might be an alternative treatment for BPH. BoNT injections have several advantages over drugs and surgical therapies in the management of intractable or chronic disease; systemic pharmacologic effects are rare, permanent destruction of tissue does not occur, and graded degrees of relaxation may be achieved by varying the dose injected. In this paper, clinical experience over the last years with BoNT in BPH impaired patients will be illustrated.

show abstract

“…Although it is not life-threatening, its clinical manifestation as lower urinary tract symptoms (LUTS) can affect the patient's quality of life. 1 Up to 30% of men older than 65 may experience distressing LUTS. BPH is a compilation of irritative voiding and obstructive symptoms which are consistent with reduced emptying of urine from and defective storage of urine in the bladder.…”

Section: Introductionmentioning

confidence: 99%

“…It was reported that about 30% of all male patients who live to the age of 80 years will need a prostatectomy for serious voiding symptoms of BPH. 1 In a survey of 19.165 people from general population 64.3% of participants reported at least one LUTS. The prevalence has increased to 80.7% in men ≥60 years old.…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of silodosin-a review of literature

Faikoglu¹,

Saygisever-Faikoglu²,

Ozcan³

et al. 2021

PPIJ

View full text Add to dashboard Cite

Background: Benign prostatic hyperplasia is a compilation of irritative voiding and obstructive symptoms which are consistent with reduced emptying of urine from and defective storage of urine in the bladder. Medications are a common method of treatment to delay complications and reduce symptoms. Silodosin is a highly selective alpha-1A adrenoceptor blocker that has 162 times more affinity for alpha-1a than alpha 1b, thus resulting in high uroselectivity and decreased side effects. Aim:In this review article our aim was to elucidate the clinical effects, safety and tolerability profile of silodosin in the treatment of benign prostatic hyperplasia.Method: Literatures were retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., silodosin, hypotension, benign prostatic hyperplasia), without any limitations in terms of publication date and language. Papers which assessed the therapeutic efficacy and tolerability of silodosin were selected for inclusion according to their relevance for the topic, as judged by the authors. Overvıew of clinical data:Silodosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. It has a rapid onset of effect in men with lower urinary tract symptoms and improvements were seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life. The efficacy of silodosin was maintained in several controlled studies and also non-interventional real-world setting. Silodosin was generally well tolerated. Conclusion:Silodosin is the most uroselective α-blocker. Silodosin has been emphasized in the 2021 European Association of Urology Conservative treatment of non-neurogenic male LUTS guidelines and it has been reported that the hypotensive effect of silodosin is comparable with placebo and has favorable safety and tolerability profile. Dosing of silodosin does not need to be adjusted according to age, concurrent medication with antihypertensives and phosphodiesterase type 5 inhibitors.

show abstract

Benign Prostatic Hyperplasia: Symptoms, Symptom Scores, and Outcome Measures

Cited by 7 publications

References 11 publications

Nocturnal polyuria in men performing uroflowmetry for lower urinary tract symptoms

Nocturnal polyuria in men performing uroflowmetry for lower urinary tract symptoms

Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin

The efficacy and safety of silodosin-a review of literature

Contact Info

Product

Resources

About